SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as community members discuss its potential due to privacy features and fixed supply, drawing comparisons to Bitcoin. Some speculate on possible catalysts while others point to technical indicators suggesting continued upward momentum. The coin's privacy-focused nature and historical price movements are also being actively considered.

Valvoline, Inc. engages in the production, marketing, and supply of engine and automotive maintenance products and services. It operates through the Retail Services segment. The Retail Services segment services the passenger car and light truck quick lube market in the US and Canada with preventive maintenance services done through company operated and independent franchise care stores. The company was founded by John Ellis in 1866 and is headquartered in Lexington, KY.

Valvoline Inc

Valvoline is trending as investors discuss the company's plans to open a record number of new stores, including EV service locations, and community members are highlighting its potential to test all-time highs. Bullish sentiment is growing, with many viewing it as a safe, long-term hold and a smart money play. Additionally, Piper Sandler recently updated their rating on Valvoline.

VanEck ETF Trust - VanEck Junior Gold Miners ETF

VanEck Junior Gold Miners ETF

GDXJ is trending as junior gold miners exhibit strong momentum, with some analysts pointing to a potential breakout and new targets. Community discussion revolves around Elliott Wave analysis, identifying key support levels and bullish nesting structures. Broader market factors, including central bank activity and the weakening dollar, are also being considered as potential catalysts for further upside.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as the community discusses its potential following upcoming changes to the token's structure and sunsetting of $PRQ. Integrations with platforms like Shogun and NewEra are also driving interest, with community members pointing to the growing adoption of Reactive contracts for cross-chain automation. Bullish sentiment is building as traders anticipate new exchange listings and increased volume.

ProShares Trust - ProShares VIX Mid-Term Futures ETF

ProShares VIX Mid-Term Futures ETF

VIXM is trending as traders assess the potential impact of a possible government shutdown and its effect on market volatility. The community is weighing the ETF as a hedge against increasingly "frothy" market conditions, with some considering longer-term options strategies. Discussion also centers on the ETF's potential as a minimal decay insurance play compared to other volatility products.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as the community debates its potential, particularly compared to other crypto projects and its real-world utility.  Some investors are expressing frustration with HBAR's price action relative to meme coins, while others are anticipating positive catalysts such as potential ETF approvals and are accumulating. Discussions also revolve around upcoming network upgrades and their impact on scalability and enterprise adoption.

ARK Investment Management LLC - ARK Genomic Revolution ETF

ARKG is trending as traders discuss potential breakouts and long-term growth catalysts within the genomics sector. Community members are weighing the ETF's potential for a significant move, citing technical indicators and possible tailwinds from AI advancements in healthcare. Despite mixed sentiment regarding management, some see an opportune entry point amid broader market discussions.

iShares Trust - iShares Lithium Miners and Producers ETF

iShares Lithium Miners and Producers ETF

ILIT is trending as the lithium sector reacts to news of a production halt at a major Chinese lithium mine, sparking discussions about potential supply rebalancing and price volatility. The community is evaluating the ETF's recent performance relative to other metal and commodity ETFs, noting its potential for future growth amid anticipated infrastructure build-out.

NexMetals Mining Corp. is a mineral exploration and development company. It engages in the exploration, evaluating and development of nickel, copper, cobalt, and platinum group metals resources. The company was founded on September 23, 1983 and is headquartered in Toronto, Canada.

NexMetals Mining Corp.

NexMetals is trending following positive reports regarding its Botswana mining operations, particularly the Selebi and Selkirk projects, with the community highlighting the potential for increased copper output. Recent metallurgical breakthroughs allowing for separate, saleable copper and nickel concentrates are being viewed as a major step forward, potentially de-risking development and improving project economics. Traders are also noting the stock's low RSI and potential for a rebound.

Roundhill ETF Trust - Roundhill TSLA WeeklyPay ETF

Tradr 1.5X Long TSLA Weekly ETF

TSLW is trending as traders discuss its weekly dividend payouts and technical analysis, with some expressing interest in accumulating shares during dips. Community members are actively sharing their strategies, including adding to positions and monitoring trend lines for potential buying opportunities, while also comparing TSLW's performance against similar leveraged ETFs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Avidity Biosciences, Inc. (RNA) fell 20% in the pre-market session on Thursday after the company announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-proposed-public-offering-of-common-stock-302553124.html">stated</a> that it intends to grant the underwriters an option to purchase up to an additional $75 million of shares, while adding that there can be no assurance as to whether or when the offering may be completed.The proceeds of the offering are expected to advance the development of the company’s three late-stage clinical programs, help build appropriate commercial inventory levels to support multiple potential launches, and expand its commercial infrastructure. The company also intends to progress research and development associated with its Antibody Oligonucleotide Conjugates platform and use the proceeds for working capital and general corporate purposes.Avidity had cash, cash equivalents, and marketable securities totaling approximately $1.2 billion as of June 30. It had stated in August that it expects to have sufficient funds for its operations through mid-2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNA">RNA stock</a> rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1360/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_7_16_45_AM_png_8af84254fb.webp" alt="RNA's Sentiment Meter and Message Volume as of 7:17 a.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="1360" height="122"><figcaption>RNA's Sentiment Meter and Message Volume as of 7:17 a.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that Avidity stock has a good chance of hitting $100 in a year.<stembedurl>https://stocktwits.com/dgbio/message/628258214</stembedurl>The Financial Times <a href="https://stocktwits.com/news-articles/markets/equity/novartis-reportedly-eyeing-to-acquire-avidity-biosciences/chrSPptRd5k">reported</a> last month that Novartis made a takeover approach for Avidity, adding that the discussions were at an early stage and might not result in a deal.Avidity has three programs under development for three distinct rare diseases affecting the muscles: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD). Bank of America raised its price target on Avidity to $56 from $54 on Thursday, while maintaining a ‘Buy’ rating on the shares. The firm pinned the price target hike on recent study results, which showed that treatment with Avidity’s Del-zota reversed disease progression in patients with DMD.RNA stock is up by about 60% this year and by about 14% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-higher-ahead-of-cpi-report/chwN03BRdv4">Dow Futures Edge Higher As Wall Street Awaits Consumer Inflation Data: ORCL, OPEN, KLAR, ADBE Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is Avidity Biosciences Stock Down 20% Pre-market Today?

Avidity said on Thursday that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.

Equity

Avidity said on Thursday that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.


RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.

Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of -59.18% and -73.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Novartis AG (NVS) has made a takeover approach for San Diego-headquartered Avidity Biosciences (RNA), Financial Times <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/0e2c4788-141c-4dcf-9da9-1c3c6ab9dde1">reported</a> on Wednesday, citing people familiar with the matter.Novartis has been evaluating a bid for Avidity and expressed interest in an acquisition in recent weeks, the report said. The discussions are at an early stage and might not result in a deal, sources told FT.However, a takeover for Avidity would probably come with a premium, the people added.Shares of Avidity were trading 22% higher at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNA">Avidity</a> trended in the ‘extremely bullish’ territory over the past 24 hours, coupled with ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1252/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_12_23_34_PM_png_eab16d508a.webp" alt="RNA's Sentiment Meter and Message Volume as of 12:23 a.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="1252" height="126"><figcaption>RNA's Sentiment Meter and Message Volume as of 12:23 a.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that they do not see the company management selling it for less than $70 or $80 per share, implying a significant premium to current price levels. &nbsp;<stembedurl>https://stocktwits.com/Atomickb/message/623958052</stembedurl>Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">Novartis</a> jumped from ‘bearish’ to ‘neutral’ over 24 hours, accompanied by ‘normal’ levels of retail chatter.<figure class="image"><img style="aspect-ratio:1254/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_12_23_08_PM_png_0f5356da43.webp" alt="NVS's Sentiment Meter and Message Volume as of 12:23 a.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="1254" height="126"><figcaption>NVS's Sentiment Meter and Message Volume as of 12:23 a.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure> Avidity has three programs under development for three distinct rare diseases affecting the muscles: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD).Novartis, meanwhile, is looking to lose patent protection in the U.S. for some of its best-selling drugs, including heart failure drug Entresto and Xolair, used to treat several allergic conditions.In February, Novartis also agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company, for $925 million upfront.While NYSE-listed shares of Novartis are up by 17% this year, RNA stock soared 60%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/marco-rubio-swiss-president-discuss-39-tariffs-on-switzerland/chrScI0Rd5K">Marco Rubio, Swiss President Discuss 39% Tariffs On Switzerland</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium

Novartis has been evaluating a bid for Avidity and expressed interest in an acquisition in recent weeks, FT reported.

Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance

Citi says SMid biotechs alternative to large caps as it starts coverage

Investing.com -- Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to large-cap pharmaceutical firms, particularly amid healthcare policy uncertainties. Citi initiated coverage with Buy ratings on 89bio (NASDAQ:ETNB), price target $25. Apogee (NASDAQ:APOG), price target $95. Avidity, price target $70, BioNTech (NASDAQ:BNTX), price target $145. Kiniksa, price target $40. Kymera, price target $52

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.14	--	--	N/A
Q2 '25	-$0.96	-$1.21	-26.28%	MISSED
Q1 '25	-$0.88	-$0.90	-2.80%	MISSED
Q4 '24	-$0.79	-$0.80	-1.04%	MISSED
Q3 '24	-$0.71	-$0.65	8.63%	BEAT

RNA
Avidity Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest RNA News

RNA Avidity Biosciences Inc